CAMBRIDGE, MA – November 18, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today a second clinical trial supply agreement with Novartis to evaluate HiFiBiO’s HFB200603, a novel anti-BLTA monoclonal antibody in combination with tislelizumab, Novartis anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug … Continued

CAMBRIDGE, MA – September 5th , 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that clinical trial investigator, Anthony B. El-Khoueiry, MD, Associate Director for Clinical Research and Phase I Program Director at the University of Southern California, Norris Comprehensive Cancer Center, and Associate Professor of Clinical Medicine at the Keck School … Continued

CAMBRIDGE, MA – August 15, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today a clinical trial supply agreement with Novartis to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with HiFiBiO’s HFB200301, an investigational first-in-class monoclonal anti-TNFR2 agonist antibody for the potential treatment of advanced solid tumor indications preselected by HiFiBiO’s … Continued